United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Purchases Shares of 234,551 Royalty Pharma PLC $RPRX

Key Points

• United Super Pty Ltd disclosed a new fourth-quarter stake in Royalty Pharma, buying 234,551 shares valued at about $9.06 million.
• Institutional interest remains broad, with hedge funds and asset managers making small additions to their positions; overall, institutions own 54.35% of Royalty Pharma's stock.
• Analysts remain upbeat on RPRX, with a consensus Buy rating and target price of $53.71, while the stock recently traded near its 12-month high after the company beat EPS estimates in its latest quarterly report.

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund purchased a new stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 234,551 shares of the biopharmaceutical company's stock, valued at approximately $9,063,000.

A number of other hedge funds also recently made changes to their positions in the stock. Strs Ohio boosted its holdings in shares of Royalty Pharma by 2.8% in the 4th quarter. Strs Ohio now owns 9,318 shares of the biopharmaceutical company's stock valued at $360,000 after purchasing an additional 252 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in shares of Royalty Pharma by 0.6% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 43,287 shares of the biopharmaceutical company's stock valued at $1,673,000 after purchasing an additional 255 shares during the last quarter. Cary Street Partners Financial LLC boosted its holdings in shares of Royalty Pharma by 1.1% in the 4th quarter. Cary Street Partners Financial LLC now owns 24,405 shares of the biopharmaceutical company's stock valued at $943,000 after purchasing an additional 260 shares during the last quarter. Private Trust Co. NA boosted its holdings in shares of Royalty Pharma by 52.9% in the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 288 shares during the last quarter. Finally, Hudson Bay Capital Management LP boosted its holdings in shares of Royalty Pharma by 1.0% in the 3rd quarter. Hudson Bay Capital Management LP now owns 29,384 shares of the biopharmaceutical company's stock valued at $1,037,000 after purchasing an additional 289 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Analyst Upgrades and Downgrades

RPRX has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of Royalty Pharma from a "buy" rating to a "strong-buy" rating in a report on Saturday, May 9th. The Goldman Sachs Group reiterated a "buy" rating on shares of Royalty Pharma in a research note on Thursday, February 12th. Morgan Stanley boosted their price objective on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an "overweight" rating in a research note on Friday, April 10th. TD Cowen restated a "buy" rating on shares of Royalty Pharma in a report on Friday, February 27th. Finally, UBS Group lifted their target price on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a "buy" rating in a report on Tuesday, April 21st. Seven research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $53.71.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $54.48 on Friday. Royalty Pharma PLC has a 12 month low of $32.29 and a 12 month high of $54.74. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66. The firm has a market capitalization of $31.37 billion, a P/E ratio of 37.06, a P/E/G ratio of 1.48 and a beta of 0.40. The company's fifty day moving average price is $49.69 and its two-hundred day moving average price is $44.38.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 EPS for the quarter, topping analysts' consensus estimates of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The firm had revenue of $630.58 million for the quarter, compared to analyst estimates of $881.69 million. On average, research analysts anticipate that Royalty Pharma PLC will post 5.05 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a $0.235 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.94 annualized dividend and a yield of 1.7%. Royalty Pharma's dividend payout ratio is currently 63.95%.

Insider Activity at Royalty Pharma

In other news, Director Gregory Norden sold 3,045 shares of the company's stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $53.00, for a total value of $161,385.00. Following the sale, the director owned 191,803 shares in the company, valued at approximately $10,165,559. This represents a 1.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 13,684 shares of the company's stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $52.75, for a total transaction of $721,831.00. Following the completion of the sale, the executive vice president owned 18,197 shares in the company, valued at approximately $959,891.75. This trade represents a 42.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 233,976 shares of company stock valued at $11,710,449 over the last ninety days. Corporate insiders own 18.84% of the company's stock.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma PLC (NASDAQ:RPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.